A Real-world Prospective Study of Mother-to-child Transmission of HBV in China Using a Mobile Health Application (Shield 01)
A Real-world Prospective Study of Mother-to-child Transmission of HBV in China Using a Mobile Health Application (Shield 01)
复制标题
使用移动健康应用程序对中国乙型肝炎母婴传播进行的现实世界前瞻性研究（Shield 01）
DOI：
10.14218/jcth.2019.00057
复制
发表时间：
2020-01-01
影响因子：
3.6
通讯作者：
Hou, Jinlin
中科院分区：
文献类型：
--
作者：
Yin, Xueru;Han, Guorong;Hou, Jinlin
背景和目标：世界卫生组织（WHO）西太平洋区域制定了到2030年消除B型肝炎病毒（HBV）母婴传播（MTCT）的目标。为了评估这一目标在中国的可行性，我们进行了一项流行病学研究，以调查现实世界中母婴传播的现状。方法：收集10所医院1008例B肝炎表面抗原阳性孕妇。对婴儿进行免疫预防。此外，建议HBV DNA水平> 2，000，000 IU/mL的母亲在妊娠后期开始抗病毒治疗。一个名为SHIELD的健康应用程序被用来管理这项研究。结果：905名登记的母亲，924名婴儿，完成了随访。出生后24 h内分别有99.7%和99.7%的婴儿接种了大剂量B肝炎疫苗和B肝炎免疫球蛋白。接受抗病毒治疗的母亲446例，其中HBVDNA水平> 200万IU/mL者占72.3%，HBVDNA水平正常者占21.0%
Background and Aims: The World Health Organization (WHO) Western Pacific Region set a target of eliminating mother-to-child transmission (MTCT) of hepatitis B virus (HBV) by 2030. To assess the feasibility of this target in China, we carried out an epidemiological study to investigate the status quo of MTCT in the real-world setting. Methods: One thousand and eight hepatitis B surface antigen-positive pregnant women were enrolled at 10 hospitals. Immunoprophylaxis was administered to infants. In addition, mothers with HBV DNA level >2,000,000 IU/mL were advised to initiate antiviral therapy during late pregnancy. A health application called SHIELD was used to manage the study. Results: Nine hundred and five of the enrolled mothers, with 924 infants, completed the follow-up. Birth-dose hepatitis B vaccine and hepatitis B immunoglobulin were received by 99.7% and 99.7% of infants, respectively, within 24 h after birth. There were 446 mothers who received antiviral therapy, including 72.3% of the mothers with HBV DNA level >2,000,000 IU/mL and 21.0% of the mothers with HBV DNA level